Good morning, everyone, welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and teleconferences has predictably returned. But what can you do? The world keeps spinning, wobbly as it may appear. So to cope, we are firing up our trusty coffee kettle and brewing a few cups of stimulation. Support your neurons today. Meanwhile, here are a few tidbits to get you started. Hope your day goes well and, of course, do keep in touch. We appreciate your tips and insights. …

Regeneron Pharmaceuticals (REGN) will pay $800 million to Alnylam Pharmaceuticals (ALNY) to leverage its gene silencing technique for developing new therapies and become its exclusive partner for new drugs focused on the central nervous system or the eye, STAT reports. The collaboration will combine Regeneron’s genetic research with Alnylam’s technology, which centers on RNA interference, or RNAi, technology that uses small bits of the chemical messenger RNA to block genetic messages from cells. Regeneron and Sanofi (SNY) are ending most of an RNAi pact, PMLive notes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy